Virtual Library

Start Your Search

Gina Paola Saavedra

Author of

  • +

    EP1.03 - Biology (ID 193)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Biology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.03-02 - Frequency of Microsatellite Instability in Patients with Primary Non Small Lung Cancer in a Single Institution from Colombia (Now Available) (ID 322)

      08:00 - 18:00  |  Author(s): Gina Paola Saavedra

      • Abstract
      • Slides


      Lung carcinogenesis is a focus of research for prognosis and development of possible therapeutic objectives. The microsatellite instability (MSI) has been described as a potential mechanism of cancer development mainly in colorectal cancer as a marker of prognosis and treatment response. In lung cancer is not known the precise frequency of MSI and its possible implications for precision therapeutics. Past trials reported a low incidence of this biological signature, but this finding could improve some immune characterization of lung cancer focused in immunotherapeutics. Is very important to know the incidence of MSI in lung cancer in a sample of latin patients to know its indicence y relation with some clinical features.


      The present study is a case series were we describe microsatellite instability (MSI) in patients with primary non small cell lung cancer. First, the patients with non-small cell lung carcinomas of the Hospital Militar Central diagnosed between january 2010 and january 2016 were included, then the clinical charts of each patient were reviewed to identify clinical and socio-demographic variables. The immunohistochemical staining were realized in the paraffin blocks using the Ventana Benchmark Ultra and GX equipment allowing the identification of the mismatch repair proteins (MMRP) MLH1, PMS2, MSH2 y MSH6; defining microsatellite instability with the negativity for any of these markers. We reviewed other molecular biology signatures : EGFR mutation and KRAS in some cases were this finding could be avaliable. In Colombia there´s no health system coverage for this mutations.


      33 patients with non-small cell lung carcinoma were included in the study. Of this patients we can identify 69.7% with lung adenocarcinoma and 30.3% with squamous cell lung carcinoma. 54.5% of the total of patients were diagnosed in stage IV (TNM 7th edition). We identified a history of tobacco exposition in 45.5% of this patients. In the immunohistochemical staining, we identify that 9.1% of all the patients had microsatellite instability (MSI high); with negativity for the expression for MHL1 gene in 2 patients and for MSH6 gene in 3 patients, all of this patients were diagnosed with lung adenocarcinoma and all of this patients were EGFR wild type, in 1 of this patients we found a registry of KRAS mutated tumor. For the MHL1-negative patients, one of them had tobacco exposition history (heavy smoker) and for the MSH6-negative patients 2 of 3 had a tobacco exposition history. Unfortunately we didn´t found any of this patients treated with immunooncology agents.


      In a small latin population at a single institution the present study found a frequency of 9.1% in 33 patients with non-small cell lung cancer with microsatellite instability (MSI-High). All of this patients were adenocarcinoma subtype, non related with EGFR mutations and with a correlation with tobacco exposure. Unfortunately this is a small case series and we could not establish a response to immunooncology agents because in Colombia we have this medications available since 2018. The frequency of this finding is higher than previous reports and must be confirmed in a multiinstitutional registry from latin population in development.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.